TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06085300

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sentence recast
Description: Recast therapy is a well-established treatment for grammar in children with DLD. In this treatment, the adult repeats the child's own utterance, altering it to include the taught structure. It yields consistent large effect sizes (Hedge's g = 0.7-1.0) when focused on a single target and provided at a high dose (10-20 hrs. of therapy at a rate of \~1 recast/minute or \~600-1000 recasts total) for both morphology and syntax .

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sentence recast
Description: Recast therapy is a well-established treatment for grammar in children with DLD. In this treatment, the adult repeats the child's own utterance, altering it to include the taught structure. It yields consistent large effect sizes (Hedge's g = 0.7-1.0) when focused on a single target and provided at a high dose (10-20 hrs. of therapy at a rate of \~1 recast/minute or \~600-1000 recasts total) for both morphology and syntax .

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sentence recast
Description: Recast therapy is a well-established treatment for grammar in children with DLD. In this treatment, the adult repeats the child's own utterance, altering it to include the taught structure. It yields consistent large effect sizes (Hedge's g = 0.7-1.0) when focused on a single target and provided at a high dose (10-20 hrs. of therapy at a rate of \~1 recast/minute or \~600-1000 recasts total) for both morphology and syntax .
Study: NCT06478381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L218CAR19
Description: L218CAR19 is intravenously administered at three dose levels.
Study: NCT06240910

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurodynamics
Description: Neuro dynamics involving Stretching and gliding of the Sciatic nerve (performing each exercise for 30 s at a slow and comfortable pace of 1 repetition per \~3-4 s. The participants rested for 60 s between each exercise.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic training
Description: Aerobic exercise will involve warm-up by stretching and flexibility exercises for 5 minutes, Treadmill walking for 6 minutes, and Stationary bicycle for 6 minutes
Study: NCT05825677

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS actif
Description: Active brain stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS Sham
Description: Sham brain stimulation
Study: NCT05152797

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous tumor-infiltrating lymphocytes
Description: Fresh tumor samples will be resected from enrolled patients. Autologous TILs will be extracted and reinfused to corresponding patients after ex vivo stimulation, activation and extensive expansion.
Study: NCT05319990

Intervention type: DRUG
Intervention: Aminohippurate Sodium Inj 20% Diagnostic aid/agent used to measure effective renal plasma flow (ERPF)
Description: PAH (Basic Pharma, Geleen, Netherlands) has been used to measure ERPF in human research for 7 decades, and is very well tolerated and generally recognized as safe with low toxicity.

Intervention type: DRUG
Intervention: Iohexol Inj 300 MG/ML Diagnostic aid/agent used to measure glomerular filtration rate (GFR)
Description: Iohexol (Omnipaque 300, GE Healthcare, Chicago, IL) is a nonionic, low osmolar contrast agent with a history of extensive use in Radiology practice (for contrast x-rays) that shares many qualities of an ideal GFR marker, like inulin, such as not being absorbed, metabolized, or secreted by the kidney.
Study: NCT05723900

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Castor oil
Description: Procedure :pulpotomy procedure and histological evaluation. A sample of sixty two primary teeth from thirty healthy cooperative children of both sexes who were between 7-9 years and referred to Pediatric Dentistry Department. Two sound teeth without pulpotomy procedure were extracted and subjected to histological procedures to examine the normal pulp tissue and tissue organization (Negative control). The pulpotomy procedure was performed in sixty primary teeth (by split mouth design).~group I treated with castor oil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formocresol
Description: Group II treated with formocresol
Study: NCT05479110

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Empathy experience courses and case-base clinical reasoning
Description: Four 3-hour training sessions over 2 weeks, which included group instruction on empathy experience, clinical reasoning, and functional therapy case-oriented learning.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: case studies
Description: active control: case studies(text)
Study: NCT06002438

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whole egg powder
Description: 15g daily dose for 24 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Corn powder
Description: 15g daily dose for 24 weeks
Study: NCT05845346

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electrotherapy-Transcutaneous Electrical Stimulation (TENS)
Description: Ten electrotherapy sessions lasting 30 minutes were carried out. Analgesic currents of the TENS type, placed in the cervical region.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Massage therapy
Description: Ten massage therapy sessions lasting 20 minutes each were carried out. Techniques such as superficial rubbing, deep rubbing, kneading and gliding pressure were performed on the cervical region.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Massage therapy
Description: Ten massage therapy sessions lasting 20 minutes each were carried out. Techniques such as superficial rubbing, deep rubbing, kneading and gliding pressure were performed on the cervical region.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stretching exercises
Description: Ten stretching exercise sessions.The stretching exercise modality performed consisted of passive static stretching with a sequence of 30s-10s-30s-10s.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ischaemic Compression Technique
Description: Ten Ischaemic Compression Technique sessions. The execution of the technique is described as follows: after locating a painful point (trigger point), pressure is applied until pain is generated, then a position is sought where the pain disappears, the position of maximum comfort, which is maintained for 90 seconds (sec), after which time the patient is returned to the starting position in a passive manner.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ischaemic Compression Technique
Description: Ten Ischaemic Compression Technique sessions. The execution of the technique is described as follows: after locating a painful point (trigger point), pressure is applied until pain is generated, then a position is sought where the pain disappears, the position of maximum comfort, which is maintained for 90 seconds (sec), after which time the patient is returned to the starting position in a passive manner.
Study: NCT04933266

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subpectoral plexus block (low dose)
Description: It is one type of peripheral nerve blocks for surgery over the chest. Patients will have an ultrasound scan and nerve block with local anesthetic (LA) agent (0.25% levobupivacaine 10ml) injected 2 target sites through one skin puncture. One at the myofascial plane between the pectoralis major and minor (5ml of LA) and then under direct ultrasound visualization, the needle will be redirected and the remaining 5ml of LA will be injected at the plane between the pectoralis minor and the serratus anterior muscle, close to the origin of thoracoacromial artery from the axillary artery at the level of the third rib.
Study: NCT06002438

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Supercereal Plus
Description: Approximately 110 g per day (1.5 kg every 2 weeks) supplementary food to be provided for treatment of MAM for up to 6 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Supercereal Plus
Description: Approximately 110 g per day (1.5 kg every 2 weeks) supplementary food to be provided for treatment of MAM for up to 6 weeks.
Study: NCT04096378

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EMBRace Intervention Group
Description: The EMBRace intervention will consist of five weekly sessions (weeks 2 - 6) that will be facilitated by EMBRace-trained therapists. Throughout the 8-week intervention, families will be scheduled for 2-hour blocks with sessions being administered to each parent and adolescent for 90 minutes (individually for 30 minutes, 15-minute break, and 45-minutes session with parent and adolescent together). The sessions will cover research-based types of Racial Socialization, including cultural pride, preparation for bias, and attentiveness and balance towards societal racism. Parents and youth will also learn and practice five literacy skills to process and manage the stress of racial encounters including the ability to recognize racial discrimination, accurately appraise the stress of self and others, reduce one's stress, engage instead of avoid, and finally resolve toward healthy outcomes.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: EMBRace Waitlist Group
Description: The waitlist group will be asked to complete a pretest and posttest while the treatment group goes through the EMBRace intervention. During this time, the waitlist group will not have any additional requirements and will not be given any form of comparative treatments. Upon the completion of the treatment from the intervention group, the waitlist group will be consented for entry into the intervention arm of the study and will follow the procedures for the intervention group above.
Study: NCT06002438

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Micronutrient sprinkles
Description: To be provided after completion of MAM supplementary feeding. Provides 1 RDA of 14 micronutrients.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Micronutrient sprinkles
Description: To be provided after completion of MAM supplementary feeding. Provides 1 RDA of 14 micronutrients.
Study: NCT05337020

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey
Description: Each patient will be asked to fill in the questionnaire to assess their vision on telemedicine
Study: NCT04933266

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subpectoral plexus block (High dose)
Description: It is one type of peripheral nerve blocks for surgery over the chest. Patients will have an ultrasound scan and nerve block with local anesthetic (LA) agent (0.25% levobupivacaine 20ml) injected 2 target sites through one skin puncture. One at the myofascial plane between the pectoralis major and minor (10ml of LA) and then under direct ultrasound visualization, the needle will be redirected and the remaining 10ml of LA will be injected at the plane between the pectoralis minor and the serratus anterior muscle, close to the origin of thoracoacromial artery from the axillary artery at the level of the third rib.
Study: NCT05463809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Continuous Gastrocnemius plane block with ropivacaine
Description: After extubation, the patient was routinely monitored for his vital signs.The nerve block operation was performed by the same doctor: let the patient take the lateral decubitus position, use the ultrasonic high-frequency array probe under the popliteal socket to scan the sciatic nerve, move the probe down to find the tibial nerve and the common peroneal nerve, and then a single injection of 0.375% Ropivacaine 15milliliters was given into the common peroneal nerve, medial sural cutaneous nerve, and lateral sural cutaneous nerve. Then avoid common peroneal nerve, use the indwelling needle (16GA 3.25 IN), and put the catheter after saline expansion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxycodone
Description: The patient was revived and received intravenous oxycodone titration according to the numerical rating scale (NRS) score, and was treated with no background dose of oxycodone patient-controlled intravenous analgesia (PCIA) pump for analgesia.
Study: NCT06002438

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulfadoxine pyrimethamine
Description: Infants \< 12 months of age: 250/12.5mg SP at enrollment, week 6, week 12, week 18.~Infants \>= 12 months of age: 500/25mg SP at enrollment, week 6, week 12, week 18.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfadoxine pyrimethamine
Description: Infants \< 12 months of age: 250/12.5mg SP at enrollment, week 6, week 12, week 18.~Infants \>= 12 months of age: 500/25mg SP at enrollment, week 6, week 12, week 18.
Study: NCT05152940

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ertugliflozin
Description: Treatment with Ertugliflozin 5 mg oral once per day for one month

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ertugliflozin
Description: Treatment with Ertugliflozin 5 mg oral once per day for one month

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Treatment with matching placebo to ertugliflozin administered orally once daily for a period of one month

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Treatment with matching placebo to ertugliflozin administered orally once daily for a period of one month
Study: NCT04015830

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electroencephalography (EEG) and event related potentials (ERP)
Description: This is an exploratory study of EEG/ERP measures in older African American and Whites with HIV
Study: NCT06136936

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CT-156-C-001
Description: CT-156 is a digital therapeutic (DTx) under development to treat patients 18 years of age and older with a diagnosis of schizophrenia under standard of care therapy who are on antipsychotic medication and not currently experiencing acute hallucinations or delusions.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CT-156-C-001
Description: CT-156 is a digital therapeutic (DTx) under development to treat patients 18 years of age and older with a diagnosis of schizophrenia under standard of care therapy who are on antipsychotic medication and not currently experiencing acute hallucinations or delusions.
Study: NCT05491785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cebranopadol 600 µg
Description: Participants will be administered a single dose of 8 identically appearing capsules containing: 3 oxycodone placebo capsules, 3 cebranopadol 200 µg tablets and 2 cebranopadol placebo tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cebranopadol 800 µg
Description: Participants will be administered a single dose of 8 identically appearing capsules containing: 3 oxycodone placebo capsules, 4 cebranopadol 200 µg tablets and 1 cebranopadol placebo tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cebranopadol 1000 µg
Description: Participants will be administered a single dose of 8 identically appearing capsules containing: 3 oxycodone placebo capsules, and 5 cebranopadol 200 µg tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone 30 mg
Description: Participants will be administered a single dose of 8 identically appearing capsules containing: 3 oxycodone 10 mg capsules, and 5 cebranopadol placebo tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone 60 mg
Description: Participants will be administered a single dose of 8 identically appearing capsules containing: 3 oxycodone 20 mg capsules, and 5 cebranopadol placebo tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be administered a single dose of 8 identically appearing capsules containing: 3 oxycodone placebo capsules, and 5 cebranopadol placebo tablets
Study: NCT06123052

Intervention type: OTHER
Intervention: Interview
Description: This is a descriptive qualitative study using semi-structured individual interviews. The interview will aim to collect more information about the patients' underlying motives that influence their ability or willingness to use IBD-CE. An interview guide has been developed for this purpose, based on topics derived from the Unified Theory of Acceptance and Use of Technology (UTAUT) model, the COM-B model for behavioural change and the model of positive health. This interview guide is divided into four sections, each introduced by an initial question. Subsequent follow-up questions will be formulated based on the patients' responses.~Furthermore, patient characteristics, disease characteristics, and socio-demographic data will be collected from the Electronic Medical Record (EMR). These data will provide insights into various aspects of the patients' profiles and are based on characteristics that seem to be determinants of technology acceptance and/or digital health literacy.

Intervention type: OTHER
Intervention: Interview
Description: This is a descriptive qualitative study using semi-structured individual interviews. The interview will aim to collect more information about the patients' underlying motives that influence their ability or willingness to use IBD-CE. An interview guide has been developed for this purpose, based on topics derived from the Unified Theory of Acceptance and Use of Technology (UTAUT) model, the COM-B model for behavioural change and the model of positive health. This interview guide is divided into four sections, each introduced by an initial question. Subsequent follow-up questions will be formulated based on the patients' responses.~Furthermore, patient characteristics, disease characteristics, and socio-demographic data will be collected from the Electronic Medical Record (EMR). These data will provide insights into various aspects of the patients' profiles and are based on characteristics that seem to be determinants of technology acceptance and/or digital health literacy.

Intervention type: OTHER
Intervention: Interview
Description: This is a descriptive qualitative study using semi-structured individual interviews. The interview will aim to collect more information about the patients' underlying motives that influence their ability or willingness to use IBD-CE. An interview guide has been developed for this purpose, based on topics derived from the Unified Theory of Acceptance and Use of Technology (UTAUT) model, the COM-B model for behavioural change and the model of positive health. This interview guide is divided into four sections, each introduced by an initial question. Subsequent follow-up questions will be formulated based on the patients' responses.~Furthermore, patient characteristics, disease characteristics, and socio-demographic data will be collected from the Electronic Medical Record (EMR). These data will provide insights into various aspects of the patients' profiles and are based on characteristics that seem to be determinants of technology acceptance and/or digital health literacy.
Study: NCT04895761

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DPX-Survivac
Description: DPX is a novel formulation that when combined with target antigens acts to activate T cells. It is a lipid-based formulation that creates a long lasting depot at the site of injection, forcing an active uptake by antigen presenting cells (APCs). APCs traffic to regional lymph nodes where naïve T cells are activated, inducing strong and sustained immune responses. All arms will receive DPX-Survivac on weeks 2 and 5.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DPX-Survivac
Description: DPX is a novel formulation that when combined with target antigens acts to activate T cells. It is a lipid-based formulation that creates a long lasting depot at the site of injection, forcing an active uptake by antigen presenting cells (APCs). APCs traffic to regional lymph nodes where naïve T cells are activated, inducing strong and sustained immune responses. All arms will receive DPX-Survivac on weeks 2 and 5.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DPX-Survivac
Description: DPX is a novel formulation that when combined with target antigens acts to activate T cells. It is a lipid-based formulation that creates a long lasting depot at the site of injection, forcing an active uptake by antigen presenting cells (APCs). APCs traffic to regional lymph nodes where naïve T cells are activated, inducing strong and sustained immune responses. All arms will receive DPX-Survivac on weeks 2 and 5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole 2.5mg
Description: Aromatase inhibitor all arms will receive

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole 2.5mg
Description: Aromatase inhibitor all arms will receive

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole 2.5mg
Description: Aromatase inhibitor all arms will receive

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide 50mg
Description: oral chemotherapy used in the neoadjuvant setting for Arm C only

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: XRT 10Gy x2
Description: Directed radiation at week 4 for Arm B only
Study: NCT05831982

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Person-centered strength training and nutrition intervention
Description: Focus on high intensity strength training and nutrition intervention with focus on energy and protein intake. Focus on social relations

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard training
Description: Training as usual when discharged with a rehabilitation plan.
Study: NCT05437302

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: prism spectacle
Description: a prism is dispensed in prescription glasses

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: prism spectacle
Description: a prism is dispensed in prescription glasses
Study: NCT05977049

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Takotsubo Support Group
Description: Participants will undergo virtual group therapy/education. Participants will meet once every other week (at minimum), for 1 - 1.5 hours (on average). The frequency and/or length of the support group sessions may be adjusted according to participants' needs.